SMOKEBOT undergoes a trial by fire
Smokebot is a wifi-controlled robot that can asses the risks in a fire when visibility is very low.… READ MORE … source
Italy works on extending Alitalia loan deadline: source
ROME (Reuters) – Italy is working on an extension of as much as six months to a Dec. 15 deadline for Alitalia to repay a 900 million euro ($1 billion)…
Danske shares slide as U.S. criminal inquiry spooks investors
COPENHAGEN (Reuters) – Danske Bank’s (DANSKE.CO) deepening money laundering scandal dragged its shares to a four-year low on Friday as Denmark’s biggest bank sought to calm investors over the impact…
Honda to invest $2.75 billion in GM’s Cruise self-driving unit
WARREN, Mich (Reuters) – Honda Motor Co Ltd (7267.T) will invest $2.75 billion in General Motors Co’s (GM.N) Cruise Automation, the second outside multibillion-dollar commitment to the self-driving vehicle unit…
‘In hemp we trust’: Thousands rally for legalizing marijuana in Berlin
Thousands of protesters gathered in Berlin calling for the legalisation of cannabis. Different organisations and parties were present during the demonstration … source
Knorr-Bremse discloses dispute with Bosch in IPO prospectus
MUNICH (Reuters) – German brake maker Knorr-Bremse has disclosed a contractual dispute with Robert Bosch GmbH ahead of a stock market flotation that could raise up to 4.2 billion euros…
German elections: are refugees still welcome?
As part of our special coverage ahead of the German elections, we travel to Germany’s deep south, in the state of Bavaria. As the election draws near, tensions … source
G20 body language: Reading between the lines
A look into the body language of the world leaders at the G20 summit in Hamburg. RT LIVE http://rt.com/on-air Subscribe to RT! source
Sanctions benefit only the US: Germany, Austria call to scrap new anti-Russian measures
The new anti-Russian sanctions are outlined in an amendment to a bill imposing sanctions against Iran. The anti-Russian measures in the amendment involve … source
EU approves fifth copy of AbbVie’s $18 billion drug Humira
LONDON (Reuters) – Europe has approved a fifth copy of AbbVie’s $18-billion-a-year biologic drug Humira – the world’s best-selling prescription medicine – ramping up competition among makers of less-expensive biotech…